Homology Medicines, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 35.04 million compared to USD 29.09 million a year ago. Basic loss per share from continuing operations was USD 10.98 compared to USD 9.18 a year ago. Diluted loss per share from continuing operations was USD 10.98 compared to USD 9.18 a year ago.
For the six months, net loss was USD 63.89 million compared to net income of USD 63.02 million a year ago. Basic loss per share from continuing operations was USD 19.98 compared to basic earnings per share from continuing operations of USD 19.8 a year ago. Diluted loss per share from continuing operations was USD 19.98 compared to diluted earnings per share from continuing operations of USD 19.62 a year ago.